Skip to main content
. 2020 Jan 1;11(1):25–40. doi: 10.7150/jca.32765

Figure 7.

Figure 7

SiRNA#1-mediated TAB1 knockdown attenuates cellular function changes caused by co-treatment with MDM2/MDMX inhibitor and DOX in MCF-7/DOX cells. MCF-7/DOX cells were transfected with siRNA#1 following co-treatment with MDM2/MDMX inhibitor and DOX with appropriate agent dosages at 1:2 (siRNA: Lipofectamine 2000; μg:μg). The concentration levels of the agents that were used were 0.08 µg/ml for DOX and 9.58 µg/ml for the MDM2/MDMX inhibitor. Quantified data (A-D) of plate clone formation assay, cell cycle analysis, apoptotic assays and rhodamine123 efflux analysis are shown. The values presented are the mean ± SD for each group. *P<0.05, **P<0.01, ***P<0.001 vs. co-treatment with MDM2/MDMX inhibitor and DOX groups (n=3). MDM2, MDMX and TAB1 expression in 70 human breast cancer tissues were detected by IHC staining. Representative images for MDM2, MDMX and TAB1 are shown in (E). Magnification: 400×.